Compare · HQL vs PS
HQL vs PS
Side-by-side comparison of abrdn Life Sciences Investors Shares of Beneficial Interest (HQL) and Pershing Square Inc. (PS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HQL and PS operate in Investment Managers (Finance), so they compete in similar markets.
- PS is the larger of the two at $20.58B, about 44.3x HQL ($464.5M).
- PS has hit the wire 8 times in the past 4 weeks while HQL has been quiet.
- PS has more recent analyst coverage (13 ratings vs 0 for HQL).
abrdn Life Sciences Investors Shares of Beneficial Interest
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Pershing Square Inc.
Pershing Square Inc. is the parent company of Pershing Square Capital Management, L.P., an SEC-registered investment adviser to investment funds and other companies, based in New York.
Latest HQL
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
- SEC Form N-PX filed by abrdn Life Sciences Investors Shares of Beneficial Interest
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
- Director Mahai Chris Lavictoire bought $10,498 worth of shares (527 units at $19.92) (SEC Form 4)
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
- SEC Form 3 filed by new insider Mahai Chris Lavictoire
- SEC Form N-CSRS filed by abrdn Life Sciences Investors Shares of Beneficial Interest
- ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
Latest PS
- Director Pershing Square Capital Management, L.P. sold 0 shares and bought 0 shares (SEC Form 4)
- New insider Pershing Square Capital Management, L.P. claimed ownership of 422,533 shares (SEC Form 3)
- Pershing Square Inc. Reports Third Quarter 2026 Results
- Pershing Square Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Pershing Square USA, Ltd. to Publish its Quarterly Portfolio Review on November 2, 2026
- Pershing Square Holdings, Ltd. to Publish its Quarterly Portfolio Review on November 2, 2026
- Pershing Square Announces Dates and Times for 2026 Third Quarter Earnings Release and Conference Calls
- Pershing Square, Inc. downgraded by BofA Securities with a new price target
- Pershing Square, Inc. downgraded by Citigroup with a new price target
- Pershing Square Declares Fourth Quarter 2026 Dividend